MIRM
BEARISH
$96.49
Live
Mirum Pharmaceuticals, Inc. · NASDAQ
Target $125.36
(+29.9%)
$37.83
52W Range
$109.28
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 14, 2026
Market cap
$5.82B
P/E
N/A
ROE
-8.6%
Profit margin
-4.5%
Debt/Equity
1.02
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
MIRM exhibits severe fundamental weakness with a Piotroski F-Score of 2/9, indicating poor financial health and operational inefficiency. While the company shows impressive revenue growth of 49.8% and strong gross margins, this is offset by a lack of profitability and an extremely stretched valuation (P/B of 15.91). There is a stark divergence between the 'strong_buy' analyst consensus and the bearish reality of aggressive insider selling by the CEO, CFO, and President. The combination of a bearish technical trend (10/100) and deteriorating deterministic scores suggests the current price is speculative and unsupported by fundamentals.
Key Strengths
Strong YoY revenue growth of 49.80%
Excellent gross margins at 80.77%
Healthy short-term liquidity with a current ratio of 2.67
Strong historical 1-year price appreciation (+143.7%)
High analyst conviction with a target price of $125.36
Key Risks
Critically low Piotroski F-Score (2/9) indicating weak financial health
Aggressive insider selling across C-suite executives (CEO, CFO, President)
Extreme valuation multiples (Price/Book: 15.91, Price/Sales: 11.17)
Negative profitability and a deeply negative forward P/E (-888.74)
Strongly bearish technical trend (10/100)
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
34
Weak
15
70
65
20
0
AI Verdict
Speculative/High Risk
Key drivers: Revenue growth, Piotroski F-Score, Insider selling, Valuation multiples
Confidence
90%
Value
15/100
Stock trades at a massive premium to book value and sales.
Positives
No standout positives identified.
Watchpoints
- P/B of 15.91 is excessive
- P/S of 11.17 is high for non-profitable biotech
- No Graham Number available due to lack of earnings
Future
70/100
Growth is strong, but monetization into net profit remains elusive.
Positives
- 49.8% Revenue growth
- Strong analyst target price
Watchpoints
- Volatile EPS surprises
- Negative forward P/E
Past
65/100
Strong price momentum over the last year, though recently stalling.
Positives
- 1Y return of +143.7%
- Consistent revenue scaling
Watchpoints
- History of missing earnings estimates
Health
20/100
Deterministic health scores are in the 'Weak' category.
Positives
- Current ratio 2.67
Watchpoints
- Piotroski F-Score 2/9
- Negative ROE and ROA
Dividend
0/100
Non-dividend paying growth company.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$96.49
Analyst Target
$125.36
Upside/Downside
+29.9%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for MIRM and closest competitors.
Updated 2026-04-13
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
MIRM
Mirum Pharmaceuticals, Inc.
Primary
|
+417.6% | +286.1% | +143.7% | +33.7% | +6.4% | +0.3% |
|
BLCO
Bausch + Lomb Corporation
Peer
|
-15.1% | -0.2% | +0.8% | +18.6% | -0.2% | -1.1% |
|
CAI
Caris Life Sciences, Inc.
Peer
|
-33.0% | -33.0% | -33.0% | -40.6% | -1.3% | +4.9% |
|
LNTH
Lantheus Holdings, Inc.
Peer
|
+283.6% | -6.7% | -18.2% | +50.5% | -2.5% | +5.9% |
|
RGEN
Repligen Corporation
Peer
|
-39.7% | -30.0% | -7.4% | -11.9% | -5.7% | +1.3% |
MIR
Mirum Pharmaceuticals, Inc.
Primary
5Y
+417.6%
3Y
+286.1%
1Y
+143.7%
6M
+33.7%
1M
+6.4%
1W
+0.3%
BLC
Bausch + Lomb Corporation
Peer
5Y
-15.1%
3Y
-0.2%
1Y
+0.8%
6M
+18.6%
1M
-0.2%
1W
-1.1%
CAI
Caris Life Sciences, Inc.
Peer
5Y
-33.0%
3Y
-33.0%
1Y
-33.0%
6M
-40.6%
1M
-1.3%
1W
+4.9%
LNT
Lantheus Holdings, Inc.
Peer
5Y
+283.6%
3Y
-6.7%
1Y
-18.2%
6M
+50.5%
1M
-2.5%
1W
+5.9%
RGE
Repligen Corporation
Peer
5Y
-39.7%
3Y
-30.0%
1Y
-7.4%
6M
-11.9%
1M
-5.7%
1W
+1.3%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-888.74
PEG Ratio
N/A
P/B Ratio
15.91
P/S Ratio
11.17
EV/Revenue
11.05
EV/EBITDA
2731.73
Market Cap
$5.82B
Profitability
Profit margins and return metrics
Profit Margin
-4.48%
Operating Margin
-3.07%
Gross Margin
80.77%
ROE
-8.65%
ROA
-1.83%
Growth
Revenue and earnings growth rates
Revenue Growth
+49.8%
Earnings Growth
N/A
Q/Q Revenue Growth
+49.81%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
1.02
Moderate
Current Ratio
2.67
Strong
Quick Ratio
2.46
Excellent
Cash/Share
$6.35
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.1B
Gross Margin
81.0%
Op. Margin
-3.1%
Net Margin
-3.8%
Total Assets
$0.8B
Liabilities
$0.5B
Equity
$0.3B
Debt/Equity
1.68x
Operating CF
$0.0B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
90%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-06
$N/A
2026-02-25
$-0.12
-314.3% surprise
2025-11-04
$0.05
+131.5% surprise
2025-08-06
$-0.12
+64.0% surprise
Healthcare Sector Comparison
Comparing MIRM against 319 companies in the Healthcare sector
(20 bullish, 107 neutral, 192 bearish)
Return on Equity (ROE)
-8.65%
This Stock
vs
-86.0%
Sector Avg
-89.9%
(Below Avg)
Profit Margin
-4.48%
This Stock
vs
-11.76%
Sector Avg
-61.9%
(Weaker)
Debt to Equity
1.02
This Stock
vs
3.51
Sector Avg
-71.0%
(Less Debt)
Revenue Growth
49.8%
This Stock
vs
90.15%
Sector Avg
-44.8%
(Slower)
Current Ratio
2.67
This Stock
vs
3.67
Sector Avg
-27.1%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
MIRM
Mirum Pharmaceuticals, Inc.
|
BEARISH | $5.82B | - | -8.6% | -4.5% | $96.49 | |
|
BLCO
Bausch + Lomb Corporation
|
BEARISH | $6.01B | - | -4.5% | -6.1% | $16.98 | Compare |
|
CAI
Caris Life Sciences, Inc.
|
NEUTRAL | $5.3B | - | -45.4% | -8.4% | $18.75 | Compare |
|
LNTH
Lantheus Holdings, Inc.
|
NEUTRAL | $5.25B | 23.63 | 21.4% | 15.2% | $80.59 | Compare |
|
RGEN
Repligen Corporation
|
NEUTRAL | $6.64B | 137.0 | 2.4% | 6.6% | $117.82 | Compare |
MIRM
Mirum...
BEARISH
Mkt Cap
$5.8B
P/E
-
ROE
-8.6%
Price
$96.49
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-16 | RAMASASTRY SAIRA | Director | Sale | 2,000 | $181,520 |
| 2026-03-16 | RAMASASTRY SAIRA | Director | Option Exercise | 2,000 | $47,020 |
| 2026-03-16 | BJERKHOLT ERIC H | Chief Financial Officer | Sale | 7,287 | $670,243 |
| 2026-03-16 | PEETZ CHRISTOPHER | Chief Executive Officer | Sale | 40,985 | $3,769,714 |
| 2026-03-16 | RADOVICH PETER | President | Sale | 16,515 | $1,519,015 |
| 2026-03-16 | QUAN JOANNE | Officer | Sale | 7,287 | $670,243 |
| 2026-03-16 | HOWE JOLANDA MARIE | Officer | Sale | 4,732 | $435,239 |
| 2026-03-13 | BJERKHOLT ERIC H | Chief Financial Officer | Stock Award | 13,334 | - |
| 2026-03-13 | PEETZ CHRISTOPHER | Chief Executive Officer | Stock Award | 75,000 | - |
| 2026-03-13 | RADOVICH PETER | President | Stock Award | 30,220 | - |
| 2026-03-13 | QUAN JOANNE | Officer | Stock Award | 13,334 | - |
| 2026-03-13 | HOWE JOLANDA MARIE | Officer | Stock Award | 8,658 | - |
| 2026-03-06 | RADOVICH PETER | President | Option Exercise | 5,912 | $93,823 |
| 2026-02-13 | RAMASASTRY SAIRA | Director | Sale | 2,000 | $204,180 |
| 2026-02-13 | RAMASASTRY SAIRA | Director | Option Exercise | 2,000 | $47,020 |
RAMASASTRY SAIRA
Director
2026-03-16
2,000 shares
·
$181,520
RAMASASTRY SAIRA
Director
2026-03-16
2,000 shares
·
$47,020
BJERKHOLT ERIC H
Chief Financial Officer
2026-03-16
7,287 shares
·
$670,243
PEETZ CHRISTOPHER
Chief Executive Officer
2026-03-16
40,985 shares
·
$3,769,714
RADOVICH PETER
President
2026-03-16
16,515 shares
·
$1,519,015
QUAN JOANNE
Officer
2026-03-16
7,287 shares
·
$670,243
HOWE JOLANDA MARIE
Officer
2026-03-16
4,732 shares
·
$435,239
BJERKHOLT ERIC H
Chief Financial Officer
2026-03-13
13,334 shares
PEETZ CHRISTOPHER
Chief Executive Officer
2026-03-13
75,000 shares
RADOVICH PETER
President
2026-03-13
30,220 shares
QUAN JOANNE
Officer
2026-03-13
13,334 shares
HOWE JOLANDA MARIE
Officer
2026-03-13
8,658 shares
RADOVICH PETER
President
2026-03-06
5,912 shares
·
$93,823
RAMASASTRY SAIRA
Director
2026-02-13
2,000 shares
·
$204,180
RAMASASTRY SAIRA
Director
2026-02-13
2,000 shares
·
$47,020
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
11 analysts
TD Cowen
2026-03-27
Buy
Buy
HC Wainwright & Co.
2026-03-23
Buy
Buy
Evercore ISI Group
2026-03-04
Outperform
Outperform
Leerink Partners
2026-02-26
Outperform
Outperform
TD Cowen
2026-02-26
Buy
Buy
RBC Capital
2026-02-26
Outperform
Outperform
Citizens
2026-02-26
Market Outperform
Market Outperform
Stifel
2026-02-26
Buy
Buy
RBC Capital
2026-02-18
Outperform
Morgan Stanley
2026-01-30
Overweight
Overweight
Past News Coverage
Recent headlines mentioning MIRM from our newsroom.
Newest → oldest
No matching news yet.